Inflammatory bowel disease and spondylarthropathy

Arthritis and Rheumatism

Volumn 44, Issue 12, 2001, Pages 2728-2736

  Smale, Simon ^a   Natt, Ravinder S ^a   Orchard, Timothy R ^b   Russell, Anthony S ^c   Bjarnason, Ingvar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; HUMAN; PATHOGENESIS; PATHOLOGICAL ANATOMY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY; TREATMENT INDICATION;

HUMANS; INFLAMMATORY BOWEL DISEASES; SPONDYLARTHROPATHIES;

EID: 0035679554     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8     Document Type: Review

References (89)

1. Historical aspects of the etiology of rheumatoid arthritis
2. Gut and spondylarthropathies
3. HLA B27 related arthritis and bowel inflammation. 2. Ileocolonoscopy and bowel histology in patients with HLA B27 related arthritis
4. Gut inflammation in the pathogenesis of idiopathic forms of reactive arthritis and in the peripheral joint involvement of ankylosing spondylitis
5. Ileocolonoscopic findings in seronegative spondylarthropathies
6. Enteropathic arthritis, Whipple's disease, juvenile spondylarthropathy, uveitis, and SAPHO syndrome
7. Articular complications of ulcerative colitis
8. Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease
9. Transplantation antigens in patients with Crohn's disease: The linkage of associated ankylosing spondylitis with HLA-W27
10. Genetics of inflammatory bowel disease
11. Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history
12. Clinical phenotype is related to HLA genotype in the peripheral arthropathies in inflammatory bowel disease
13. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
14. The germfree state prevents development of gut and joint inflammatory diseases in HLA-B27 transgenic rats
15. The evolution of spondylarthropathies in relation to gut histology. III. Relation between gut and joints
16. Subclinical involvement of the gut in undifferentiated spondylarthropathies
17. Ileocolonoscopy in seronegative spondylarthropathy
18. Intestinal histological and ultrastructural inflammatory changes in spondylarthropathy and rheumatoid arthritis
19. High frequency of silent inflammatory bowel disease in spondylarthropathy
20. Macroscopic and microscopic gut lesions in seronegative spondylarthropathies
21. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: Diagnostic implications
22. Ileocolonoscopic and histologic studies of Korean patients with ankylosing spondylitis
23. Long-term evaluation of gut inflammation in patients with spondylarthropathy
24. The evolution of spondylarthropathies in relation to gut histology. II. Histological aspects
25. A prospective study of patients with spondylarthropathy with special reference to HLA-B27 and gut histology
26. Endoscopy in inflammatory bowel disease
27. Ileoscopy as an important tool for the diagnosis of Crohn's disease: A report of seven cases
28. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease?
29. The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn's disease
30. Barium studies and ileoscopy compared in children with suspected Crohn's disease
31. Expression of α/β and γδ in the ileal mucosa of patients with Crohn's disease and with spondylarthropathy
32. Quantitative faecal indium-111 labelled leucocyte excretion in assessment of disease activity in Crohn's disease
33. Sulfasalazine in the treatment of spondylarthropathy: A randomized, multicenter, double-blind, placebo-controlled study
34. Sulphasalazine in ulcerative colitis: In memorium?
35. Which component of sulphasalazine is active in rheumatoid arthritis?
36. Intestinal permeability and inflammation in patients on NSAIDs
37. Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy
38. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs
39. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs
40. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine
41. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis
42. ASA forms an ionic complex with phosphatidylcholine: Possible molecular explanation for its ulcerogenic action
43. The relative importance of inhibition of cyclooxygenase and uncoupling of oxidative phosphorylation in the gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
44. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
45. Concomitant inhibition of COX-1 and 2 underlies the intestinal toxicity of NSAIDs
46. Non-steroidal anti-inflammatory drugs and Crohn's disease
47. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin
48. Intestinal permeability: An overview
49. Intestinal permeability in ankylosing spondylitis
50. Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs
51. Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease
52. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives
53. Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives
54. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability
55. Intestinal permeability in patients with Crohn's disease and their first degree relatives
56. Intestinal permeability and inflammation in Crohn's disease and their first degree relatives
57. Intestinal permeability and inflammation in first degree relatives of patients with ankylosing spondylitis
58. Relapse of ulcerative proctocolitis during treatment with NSAID
59. Why do patients with ulcerative colitis relapse?
60. NSAID activate quiescent inflammatory bowel disease
61. Factors influencing the relapse of patients with inflammatory bowel disease
62. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years
63. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
64. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in the rat
65. A nuclear receptor to prevent colon cancer
66. Aspirin for cancer
67. Autoantibodies to HLA-B27 in the sera of HLA-B27 patients with ankylosing spondylitis and Reiters syndrome: Molecular mimicry with Klebsiella pneumonia as potential mechanism of autoimmune disease
68. Molecular mimicry and ankylosing spondylitis: Possible role of a novel sequence in pullulanase of Klebsiella pneumoniae
69. Sequential studies in ankylosing spondylitis: Association of Klebsiella pneumoniae with active disease
70. Characterization of the humoral immune response to Klebsiella species in inflammatory bowel disease and ankylosing spondylitis
71. The relationship between Klebsiella and ankylosing spondylitis
72. Molecular mimicry reflected through database screening: Serendipity or survival strategy?
73. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis and arthritis in HLA-B27/human beta2 microglobulin transgenic rats
74. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized by Bacteroides vulgatus or Escherichia coli
75. HLA-B27 does not affect invasion of arthritogenic bacteria into human cells
76. Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis
77. HLA antigens in ankylosing spondylitis associated with Crohn's disease: Increased frequency of the HLA phenotype B27
78. Ankylosing spondylitis: At the interface of bone and cartilage
79. Fibrocartilage in the heart
80. Mammalian eyes and associated tissues contain molecules that are immunologically related to cartilage proteoglycan and link protein
81. Bacterial lipopolysaccharides induce in vitro degradation of cartilage matrix through chondrocyte activation
82. Isolation of proteoglycan specific T lymphocytes from patients with ankylosing spondylitis
83. Arthritis induced by T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans
84. Proteoglycaninduced arthritis in BALB/c mice: Clinical features and histopathology
85. Genetic aspects of inflammatory bowel disease
86. Misoprostol in the treatment of NSAID-induced enteropathy: A double blind, placebo-controlled, parallel group study
87. Jejunal lesions in ankylosing spondylitis are due to nonsteroidal anti-inflammatory drug therapy
88. Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy